Cyclacel Pharma (CYCC) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Forum Energy Technologies (FET) Tops Q3 EPS by 29c ; Offers Guidance
- First Northern Community Bancorp (FNRN) Tops Q3 EPS by 38c
- FST Corp. (KBSX) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
